MacLaren, Robert E. http://orcid.org/0000-0002-3096-4682
Article History
Received: 20 February 2020
Revised: 4 May 2020
Accepted: 23 June 2020
First Online: 29 June 2020
Compliance with ethical standards
:
: The author is a named inventor on several retinal gene therapy patents owned by the University of Oxford. He is or has recently been a consultant in relation to retinal gene therapy to Novartis, Biogen, Spark Therapeutics, Gyroscope Therapeutics and the National Institute for Health and Care Excellence, which advises the UK National Health Service.